PharmaNet Professionals Addressing Challenges of Biopharmaceutical Research & Development During Drug Information Association Meeting in Philadelphia.

PRINCETON, N.J. -- Celebrating the 10th Anniversary of the Company, Representatives of PharmaNet Continue Their Long History of Support for DIA and Its Membership

Scientists and clinicians representing PharmaNet (a division of SFBC International) (NASDAQ: SFCC) are addressing many of the challenges facing the biopharmaceutical research and development industry at several sessions scheduled to take place at the upcoming Drug Information Association (DIA) annual meeting in Philadelphia, Pennsylvania (June 18 - 22, 2006).

"Many of our PharmaNet employees have been involved with the DIA throughout their careers. In each of our past ten years I have been especially proud of the number and quality of the presentations given by our staff at the annual conference," said Jeffrey P. McMullen, president and chief executive officer, PharmaNet. "Covering topics including clinical research methodologies, patient recruitment and retention, enhancing product value, regulatory strategies, training and strategic clinical trial development, some of our most talented individuals will be sharing their perspectives with participants at the DIA meeting. We are honored to have these opportunities. As well, we are very pleased to continue our long heritage of support for the DIA meeting."

Among the PharmaNet professionals scheduled to present are:

--Peggy Schrammel, executive director, late phase development - Ms. Schrammel is scheduled to chair a session entitled, "Demonstrating Product Value: Three Unique Perspectives" and is a speaker of a session entitled, "Strategies for Outsourcing and Managing Late Phase Trials Using Naive Sites." She has designed and managed the implementation of late-phase programs to demonstrate product value for numerous clients. At PharmaNet, Ms. Schrammel ensures that Late Phase Development Division programs adhere to the highest standards of scientific integrity and regulatory compliance while meeting marketing objectives.

--Duu-Gong Wu, PhD, executive director, PharmaNet consulting division - Dr. Wu is a biochemist and molecular biologist whose professional experience includes senior-level positions at the Food and Drug Administration Division of New Drug Chemistry II, with the Center for Drug Evaluation and Research. Dr. Wu is scheduled to speak in a session entitled, "Regulatory Considerations on the Development of Botanical Drug Products in the U.S."

--Bryce Bartruff, RN, MBA, PhD, manager, clinical research - Mr. Bartruff has more than 13 years of relevant clinical experience, including positions as staff nurse, clinical research associate, senior clinical research scientist and now, manager of clinical research. At PharmaNet, Mr. Bartruff has oversight of the Infectious Disease Division's efforts regarding subject recruitment and retention. He is scheduled to chair a session entitled, "Reaching Subject Recruitment and Retention Goals."

--Michael E. Laird, senior vice president, worldwide business development - Mr. Laird has more than 20 years of pharmaceutical and contract research industry experience and has held senior-level positions at Smith, Kline & French; Marion Merrell Dow; Proctor & Gamble Pharmaceuticals; and Kendle. As head of PharmaNet's global business development, Mr. Laird has daily involvement in leveraging professional resources as a differentiator among contract research organizations and is scheduled to chair a session entitled, "Intellectual Human Capital in Contract Research: Is the Market There?"

--Hani Zaki, MPH, MBA, vice president, business development - Mr. Zaki is scheduled to chair a session entitled, "Strategies for Outsourcing and Managing Late Phase Trials Using Naive Sites." Mr. Zaki has worked in both clinical research and pharmaceutical marketing since 1982, including 11 years of clinical research in oncology, infectious diseases, allergy and pulmonology, and CNS. His experience includes service with Schering-Plough, Bristol-Myers (now BMS), and Rhone-Poulenc Rorer (now Sanofi-Aventis). Mr. Zaki headed the U.S. anti-infective clinical operations group for RPR, with responsibilities for program implementation and resource allocation.

--Janet Zimmerman, MSN, senior director, training services - Ms. Zimmerman has facilitated more than 200 workshops and courses for clinical research personnel. During a healthcare career spanning more than 25 years, she has held positions as a research nurse; clinical research associate (CRA); trainer and course developer; as well as CRA training manager and is scheduled to speak at two different DIA sessions including, "GCP Training Around the Globe: Similarities and Differences and Using ADDIE to Strategically Analyze and Evaluate Your Training Program." She is also scheduled to co-present at a session entitled, "Online Learning: Managing the Implementation Process" with PharmaNet colleague Robert Morrison, RN, manager, training services. Mr. Morrison has more than 26 years of clinical experience, including the last 7 years in contract research. His previous titles have included therapeutic research associate in oncology and cardiology, senior clinical research associate, and project manager.

--Jim Downhower, MSE, senior director, IT development - Mr. Downhower has more than 15 years of experience with computer systems, including 9 years in clinical-development information technology (IT), and Kim Sanford, director, clinical data management with more than 15 years of clinical experience, including positions as CRF data scientist, senior clinical data analyst, and several positions of increasing responsibility in clinical data management, are scheduled to co-present at a session entitled, "Hybrid Data Capture Strategies."

About PharmaNet/SFBC International, Inc.

PharmaNet is the late stage division of SFBC International, Inc. As an international drug development services company, SFBC offers a comprehensive range of clinical development, clinical and bioanalytical laboratory, and consulting services to the branded pharmaceutical, biotechnology, generic drug and medical device industries. The Company has more than 30 offices, facilities and laboratories with more than 2,000 employees strategically located throughout the world. PharmaNet represents over half of the Company. PharmaNet is dedicated to providing the highest level of client satisfaction and industry-leading expertise to the pharmaceutical, biotechnology, medical device, and combined-product industries. Founded in 1996, PharmaNet today continues to deliver a positive outsourcing experience through its founding principles. For more information, visit www.sfbci.com and www.pharmanet.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, our ability to leverage the strong reputation of PharmaNet, whether adverse publicity relating to SFBC's Miami operations causes clients to select competitors, not only for early stage branded clinical trials but also for other aspects of SFBC's business; SFBC's ability to resolve open issues relating to its Miami property including whether it can successfully appeal and/or enjoin the Miami-Dade County Unsafe Structures Board ruling and any related fines or expenses if we are unsuccessful, the associated costs and expenses with discontinuing the Company's operations in Miami and Ft. Myers, whether a building permit will be issued, whether SFBC will prevail in the pending land lease litigation; continued adverse publicity related to actions of the United States Senate Finance Committee; developments with respect to the SEC's inquiry and securities class action lawsuits and derivative lawsuits; SFBC's assessment of its current FDA inspections; SFBC's ability to successfully achieve and manage the technical requirements of specialized clinical trial services, while complying with applicable rules and regulations; regulatory changes; changes affecting the clinical research industry; a reduction of outsourcing by pharmaceutical and biotechnology companies; SFBC's ability to compete internationally in attracting clients in order to develop additional business; cancellation of contracts; SFBC's ability to retain and recruit new employees; SFBC's clients' ability to provide the drugs and medical devices used in its clinical trials; SFBC's future stock price; SFBC's financial guidance; and the national and international economic climate as it affects drug development operations. Further information can be found in SFBC's risk factors contained in its Form 10-K filed with the SEC in 2006 and other filings with the Securities and Exchange Commission.